McGeorge Anne sold $845K of DNTH
McGeorge Anne sold 7,750 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $109.01 ($107.58–$111.41, $0.84M total) across 5 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the Aug 10 open-market sale of 7,750 shares by a director, totaling $844,822, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of company fundamentals in the text reduce immediate trading significance.
What to watch
The director’s post-transaction holdings are listed as 0 shares, but the article provides no context on total prior holdings or whether other insiders also sold/bought around the same period.
Background
The article is an SEC Form 4 insider transaction report for Dianthus Therapeutics, Inc. (DNTH).
Ticker impact
Dianthus Therapeutics director McGeorge Anne sold 7,750 DNTH shares for about $844,822 under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect is more about signaling than fundamentals.
The filing is a Form 4 open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying company news (earnings, guidance, trials, deals, or regulation).
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider sales under 10b5-1 can be purely mechanical and may not reflect bearish expectations.
Key entities
- issuerDianthus Therapeutics, Inc.
Company whose director insider sale is disclosed on Form 4.
- insiderMcGeorge Anne
Director who sold 7,750 shares of DNTH on Aug 10 under a 10b5-1 plan.
